Evidence map›Paper›PMID 35347561›Full record

ReviewCurrent treatment options in oncology2022

An Update on the Management of Mixed Neuroendocrine-Non-neuroendocrine Neoplasms (MiNEN).

Aasems Jacob, Rishi Raj, Derek B Allison, Heloisa P Soares, Aman Chauhan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. [Neuroendocrine carcinoma with significantly vacuolar nucleus at the esophagogastric junction: A case report].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aasems JacobDepartment of Internal Medicine, Pikeville Medical Center, Pikeville, KY, USA.
Rishi RajDepartment of Internal Medicine, Pikeville Medical Center, Pikeville, KY, USA.
Derek B AllisonDepartment of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, USA.
Heloisa P SoaresHuntsman Cancer Center, University of Utah, Salt Lake City, UT, USA.
Aman ChauhanDivision of Medical Oncology, Department of Internal Medicine, University of Kentucky, 800 Rose Street, CC447, Lexington, KY, 40536, USA. amanchauhan@uky.edu.ORCID 0000-0002-4183-2116

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementThe classification of mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) is evolving, and no clear management guidelines are currently available. However, recent studies provide insight into factors affecting outcomes and could help develop treatment decisions for patients with these rare malignancies. The majority of MiNENs have a poorly differentiated neuroendocrine carcinoma (NEC) component which is associated with an aggressive clinical course and poor outcomes. Due to the paucity of clinical trials, strategies adopted in gastrointestinal cancers and NECs are used to manage MiNENs. It is also to be noted that the thoracic neuroendocrine neoplasm WHO 2021 classification does not recognize MiNEN terminology but suggests an equivalent terminology called "combined neuroendocrine non neuroendocrine neoplasm." Surgical management is appropriate in early-stage disease with a low threshold for addition of adjuvant chemotherapy. Multimodality treatment with chemotherapy offers a survival benefit in advanced disease or when surgical resection is not possible without significant morbidity. Chemotherapy should be directed at the more aggressive component which is often the NEC component. In addition, molecular testing should be employed to evaluate patients for enrollment in clinical trials and other targeted treatments. Being a rare disease with retrospective studies and case series providing the majority of data on treatment selection, it is essential to include more granular details of pathology (e.g., Ki-67, mitotic index, percentage of each component, staging information) and treatment modalities (e.g., type and duration, rationale, radiologic response, survival outcomes) in future studies to make systematic reviews possible and help derive meaningful conclusions.

Indexed as

Gastrointestinal NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsChemotherapy, AdjuvantHumansInfant, NewbornRetrospective StudiesHepatopancreatobiliary minenLower gi minenMiNEN treatmentMixed neuroendocrine and non-neuroendocrine tumorsNeuroendocrine tumorsUpper GI minen

Identifiers

PMID35347561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.